Core Insights - The Chinese dental beauty industry is experiencing rapid growth, driven by increasing consumer demand for oral health and aesthetics, with a market size expected to exceed 78.5 billion yuan by 2025 [1][16][25] - The industry is characterized by three main features: explosive demand from 718 million oral disease patients, innovation in supply with a 25% penetration rate of invisible orthodontics, and rapid market expansion with a CAGR of 15.9% from 2018 to 2023 [1][12][16] Industry Overview - Dental beauty focuses on improving the appearance, shape, and alignment of teeth through non-invasive or minimally invasive techniques, aiming to unify natural aesthetics and functionality [2] - The industry includes various segments such as teeth whitening, veneer restoration, crown restoration, orthodontics, and gum shaping [2] Development Drivers - **Consumer Upgrade and Demand Change**: The shift from essential treatment to aesthetic consumption is evident, with over 60% of Gen Z viewing teeth whitening as key to confidence [4][16] - **Technological Innovation**: Breakthroughs in materials science and digital technology are reshaping industry standards, with AI aesthetic design and 3D printing significantly enhancing service efficiency [6][25] - **Policy and Capital Synergy**: Government initiatives like "Healthy China 2030" and increased financing are facilitating industry growth and standardization [7][25] - **Silver Economy and Niche Market Rise**: The aging population is driving demand for dental aesthetics, with 35% of spending on implants and aesthetic restorations coming from those aged 50 and above [8][25] Industry Chain - The industry chain exhibits high collaboration and vertical integration, with upstream focusing on high-value consumables and digital equipment, while domestic brands are rapidly replacing foreign ones in the mid-range market [9][20] Market Size and Growth - The market size grew from 28.56 billion yuan in 2018 to 59.82 billion yuan in 2023, with a projected growth to over 78.5 billion yuan by 2025 [16][18] Competitive Landscape - The industry features a multi-tiered competition structure, with foreign brands dominating the high-end market and domestic brands rapidly expanding in the mid-range and low-end markets [20][22] - The top five brands in the implant sector hold nearly 70% market share, while the invisible orthodontics market is dominated by two major players [20][22] Future Trends - **Technological Integration**: The industry is moving towards full-cycle intelligent management, integrating AI, 3D printing, and biological materials [25][26] - **Market Layering and Downstream Expansion**: The competition is characterized by high-end precision, mid-range differentiation, and low-end accessibility, with community health stations expanding rapidly [27][28] - **Ecosystem Reconstruction and Regulatory Upgrades**: The industry is evolving towards a cross-sector integration of healthcare, technology, and consumer services, with increased regulatory oversight [28]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [35]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 4.42% from June 27, 2025, to July 10, 2025, exceeding the CSI 300's performance by approximately 2.79 percentage points [14][29]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and in vitro diagnostics sectors leading with increases of 10.00% and 5.17%, respectively [16][29]. - Approximately 88% of stocks in the industry achieved positive returns, with notable performers including Yong'an Pharmaceutical, which saw a weekly increase of 24.71% [17][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 49.02 times as of July 10, 2025, indicating a rise in industry valuation, which is currently at a relatively low level compared to recent years [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 4.42% from June 27, 2025, to July 10, 2025 [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and in vitro diagnostics, which increased by 10.00% and 5.17%, respectively [16]. - About 88% of stocks in the industry had positive returns, with significant gains from certain stocks [17][19]. 2. Industry News - A procurement announcement for blood dialysis equipment was made, indicating a larger scale of procurement at the provincial level, which may impact pricing dynamics in the market [27]. - The report highlights the importance of the new "Occupational Disease Classification and Catalog" set to be implemented, which may influence industry practices [26]. 3. Company Announcements - Hainan Haiyao announced that its subsidiary received a drug registration certificate for Linezolid tablets, indicating progress in its product pipeline [28]. 4. Industry Outlook - The report suggests focusing on investment opportunities within the innovative drug industry chain and highlights several companies across various sectors, including medical devices, pharmaceutical commerce, and innovative drugs [31].

证券简称：通策医疗 证券代码：600763 编号：临 2025-017 通策医疗股份有限公司 关于控股股东部分股票质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 杭州宝群实业集团有限公司（以下简称"宝群实业"）持有通策医疗股份有 限公司（以下简称"公司"）股份总数 151,589,199 股，占总股本的 33.89%；本次质 押股份数为 9,660,000 股，占宝群实业所持有本公司股份数 6.37%，占本公司总股份 数的 2.16%；同时办理解除质押股份数为 9,524,046 股，占宝群实业所持有本公司股 份数的 6.28%，占本公司总股份数的 2.13%。宝群实业质押股份总数为 97,861,461 股， 占宝群实业所持有本公司股份数的 64.56%，占本公司总股份数的 21.88%；宝群实业 的一致行动人吕建明先生持股总数 2,091,088 股，占总股本的 0.47%，并无质押；宝 群实业已质押股份数占宝群实业及其一致行动人所持有本公司股份数的 63.68%，占本 公司总股 ...

关于变更办公地址的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券简称：通策医疗 证券代码：600763 编号：临 2025-016 | 变更项目 | 变更前 | | 变更后 | | | --- | --- | --- | --- | --- | | 办公地址 | 浙江省杭州市西湖区灵溪北路 | 21 | 杭州市西湖区西溪路双口井巷 | 1 号 | | | 号合生国贸中心 号楼 5 | | 通策医疗大厦 | | 通策医疗股份有限公司 通策医疗股份有限公司（以下简称"公司"）因自建总部大楼竣工投入使用，将 于 2025 年 7 月 1 日迁入新址办公。为优化投资者关系管理，便于投资者沟通，现就 公司办公地址变更事宜公告如下： 通策医疗股份有限公司董事会 2025 年 7 月 1 日 1 除上述办公地址变更外，公司注册地址、投资者热线等其他联系方式均保持不变， 提请广大投资者注意上述变更事项。 特此公告。 ...

Industry Overview - Dental implant industry involves surgical placement of artificial materials into the jawbone to serve as artificial tooth roots, followed by the installation of crowns [1] - The process includes four main steps: implant placement, waiting for osseointegration, installing abutments, and placing crowns [1] Industry Chain Analysis - The upstream of the dental implant industry includes raw material suppliers, equipment manufacturers, and software developers, with titanium and zirconia being key materials [4][5] - Midstream consists of implant manufacturers and distributors, while downstream includes dental institutions providing implant services to patients [4][5] Industry Development History - The industry has evolved through three main phases: 1. Emergence phase (1980-2000) with initial education and product development [7] 2. Dominance of foreign brands (2000-2010) with a focus on public institutions [10] 3. Rise of domestic brands (2020-present) with a shift towards high-quality local products [10] Industry Policy Direction - Policies focus on reducing medical costs, standardizing management, improving service quality, promoting talent development, and supporting digital technology applications [12] - Key policies include price standardization for dental services and promoting centralized procurement to enhance transparency and reduce costs [12][14] Current Industry Status - Dental implants account for 40% of the total implant costs, with a significant portion of the market still dominated by international brands [15][16] - The number of dental implants in China is projected to exceed 10 million by 2024, driven by increased demand and lower prices due to centralized procurement [18] Market Size and Growth - The dental implant market in China is expected to surpass 60 billion yuan by 2024, with significant price reductions leading to increased accessibility [21] - The average cost of a single implant has dropped to 5,000-7,000 yuan due to policy changes, representing a 50% decrease [21] Competitive Landscape - The market is characterized by a high concentration, with leading companies like Dentium and Osstem dominating the first tier, while others like Straumann and Nobel Biocare are in the second tier [23][26] - The market concentration ratio (CR2) is 45.78%, indicating a competitive environment with a mix of domestic and international brands [26] Future Development Trends - The demand for dental implants is expected to grow due to an aging population and increased awareness of oral health [28] - The implementation of centralized procurement policies will further stimulate market demand and enhance the penetration of domestic brands [28] - Innovations in technology, such as 3D printing and robotic-assisted surgeries, will improve the precision and efficiency of dental implants [28] - By 2030, the market size is projected to reach 277 billion yuan, with an average annual growth rate of 29% [28]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongce Medical, which closed at 40.74 yuan with a PE ratio of 35.58 times, and a total market capitalization of 18.223 billion yuan [1][2] - The average PE ratio for the medical services industry is 39.95 times, with a median of 41.77 times, positioning Tongce Medical at the 26th rank within the industry [1][2] - As of the first quarter of 2025, 21 institutions hold shares in Tongce Medical, including 18 funds, with a total holding of 209.5898 million shares valued at 9.488 billion yuan [1] Group 2 - Tongce Medical's main business focuses on providing oral medical services and research, with key products including medical services, product sales, construction engineering, and comprehensive service fees [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 745 million yuan, representing a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up by 6.22%, with a gross profit margin of 44.21% [1]

通策医疗股份有限公司 证券代码：600763 证券简称：通策医疗 编号：临 2025-015 关于 2024 年度暨 2025 年第一季度业绩暨 现金分红说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"）2024年度暨2025年第一季度业 绩暨现金分红说明会(以下简称"说明会")于2025年6月24日（星期二）15：00-16： 30于上海证券交易所上证路演中心以视频直播和网络互动方式召开。公司董事长 兼总经理王毅女士、独立董事王绪强先生、董事会秘书张华先生、财务总监徐国 喜先生等出席本次说明会，与投资者进行沟通和交流，投资者交流的主要问题及 回复概要如下： 1.2024年度及2025年Q1公司的业绩情况说明。 2024 年，面对消费需求分层、种植牙集采全面落地，行业格局加速重构， 公司稳扎稳打、稳中求进，以"医疗质量立本、客户价值为先、数据驱动创新" 为战略核心，聚焦降本增效、数字化升级与资源整合三大主线，在逆势中实现了 高质量发展。报告期内，公司实现营业收入 ...

证券简称：通策医疗 证券代码：600763 编号：临 2025-014 通策医疗股份有限公司 关于参股基金进入清算期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"、"通策医疗"）于今日收到参股基 金浙江通策壹号投资合伙企业（有限合伙）（以下简称"壹号基金"、"参股基金"） 进入清算期的通知。 一、壹号基金基本情况 医疗股份有限公司关于以妇幼子公司股权参与基金投资暨关联交易的公告》 浙江通策壹号投资合伙企业（有限合伙）系旨在从事妇幼产业专项投资业务，为 全体合伙人创造良好投资回报，实现资本增值的私募股权投资基金。 | 基金名称 | 浙江通策壹号投资合伙企业(有限合伙) | | --- | --- | | 统一社会信用代码证 | 91330624MA29DW6PX5 | | 基金编码 | SW6104 | | 基金类型 | 股权投资基金 | | 基金注册地 | 浙江省绍兴市新昌县南明街道大佛寺 8 号 1 幢 | | 基金成立日期 | 2017/9/13 | | 基金备案日期 ...

Group 1 - The core viewpoint of the article highlights the competitive landscape of the Chinese dental implant industry, focusing on market concentration and the positioning of key players [1][4][10] - The first tier of the competitive hierarchy includes Dentsply Sirona and Osstem Implant, with procurement amounts exceeding 15 million yuan, significantly surpassing other companies [1][4] - The market share of foreign brands, particularly mid-range Korean brands, is substantial, while domestic brands have a lower overall market share [4][10] Group 2 - The market concentration in the dental implant sector is high, with a CR2 of 45.78% and a CR5 of 69.94%, indicating a strong presence of leading mid-range Korean and high-end European brands [5][10] - The competitive environment is characterized by numerous players, including public dental hospitals and large chain dental institutions, which have advantages in brand recognition and technology [10][11] - The entry barriers in the dental implant industry are significant due to the need for specialized talent, advanced equipment, and time-consuming brand building [11][12] Group 3 - The regional layout of key listed companies shows that most operate primarily within China, with specific companies focusing on particular provinces, such as Keren Dental in Shandong and Blue Sky Dental in Guangxi [6][9] - Revenue from dental implant services is notably high for companies like Tongce Medical, Yaboshi, and Reer Group, indicating strong market performance [6][9] - The article emphasizes the increasing preference for dental implants over traditional dentures, as patients seek better functionality and aesthetics [11][12]

通策医疗股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600763 证券简称：通策医疗 公告编号：2025-013 会议召开时间：2025 年 06 月 24 日（星期二）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 06 月 17 日（星期二）至 06 月 23 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lianghao@eetop.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 https://roadshow.sseinfo.com/） 二、说明会召开的时间、地点 通策医疗股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发布公 司 2024 年度报告、2025 年一季度报告，为便于广大投资者更全面深入地了解公 司 20 ...